The biotech company Novavax (NVAX) announced yesterday that their COVID-19 vaccine candidate is 96.4% effective in phase 3 trial in the UK and 86% effective against the more contagious virus variant. This is huge and the stock should jump accordingly.
“Don’t let yesterday take up too much of today.” –Will Rogers